5-甲酰基尿嘧啶置于盐酸,水,Palladium Diacetate,Potassium Carbonate,R-(+)-1,1'-联萘-2,2'-双二苯膦,N,N-二异丙基乙胺,N-[(Dimethylamino)-3-Oxo-1H-1,2,3-Triazolo[4,5-B]Pyridin-1-Yl-Methylene]-N-Methylmethanaminium Hexafluorophosphate,Sodium Hydroxide,三氯氧磷体系中,用 四氢呋喃,甲醇,水,N,N-二甲基甲酰胺,异丙醇,甲苯 用作溶剂,化学反应 45.34H,反应生成Lee011琥珀酸盐 参考文献: Ribociclib Intermediate And Process For Preparation Thereof[fr] Intermédiaire De Ribociclib Et Son Procédé De Préparation 标题: Ribociclib Intermediate And Process For Preparation Thereof[fr] Intermédiaire De Ribociclib Et Son Procédé De Préparation 摘要:本发明涉及利用新型中间体制备利博西利琼琼酸盐的方法.该发明还涉及制备新型中间体的方法.
专利号:US-2022118094-A1 优先权日:2019-02-21 标题:Synthesis of biomimetic cell wall structure 发明人:WANG YONG; SHI PENG 权利人:PENN STATE RES FOUND 摘要:The present invention relates generally to methods of generating a biomimetic cell wall (BCW) on a target surface, compositions comprising the BCW, and methods of use of the compositions, including biomedical applications of the BCW coated compositions.
专利号:US-10336763-B1 优先权日:2018-05-17 标题:Crystal form B of ribociclib succinate 发明人:KAMANI SATYANARAYANA; LU TZU-CHIANG; CHANG HSIN-YUN; MAI CHIN-CHENG 权利人:CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO LTD 摘要:The present invention relates to crystal forms B, C and D of Ribociclib succinate salt and derivatives thereof, and their preparation method and composition. The crystal forms B, C and D of Ribociclib succinate salts are obtained by adding 7-cyclopentyl-N,N-dimethyl-2-(5-(piperain-1-yl)pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide solution into succinic acid solution for reaction, stirring the solution under high temperature, filtering the solution after cooling off.
专利号:US-2023391824-A1 优先权日:2021-02-08 标题:Rationale, design, synthesis and validation of a small molecule anticancer agent 发明人:JAIN MOHIT; NARENDRAN ARUMUGAVADIVEL 权利人:NARENDRAN ARUMUGAVADIVEL 摘要:LIN28 is an RNA binding protein that binds and inhibits the expression and maturation of Iet7 microRNA that carries key tumor suppressor functions. Thus, LIN28 is a feasible and effective molecular target for directed inhibition with the potential to provide therapeutic benefit to a diverse group of aggressive malignancies. The present disclosure relates generally to the Rationale, Design, Synthesis and Validation of a Novel Small Molecule Inhibitor of LIN28, coined Compound of formula (I), for the Treatment of Adult and Pediatric Malignancies. In addition, indications of this agent to block cancer metastasis, inhibit cancer stem cells to prevent relapse, and to synergize with immunotherapy, chemotherapy and radiotherapy are also been described.
专利号:US-2023160018-A1 优先权日:2020-04-16 标 题 :Crybetab2 predicts poor breast cancer outcome and sensitizes tumors to nucleolin and cdk inhibition 发明人:MERINO VANESSA FERREIRA; POMPER MARTIN; SUKUMAR SARASWATI 权利人:UNIV JOHNS HOPKINS 摘要:CKYPB2 induces EMT, sternness, protein synthesis and cell cycle progression through regulation of nucleolin, con-tributing to an increase in tumor growth and metastasis. CKYPB2 can be used as a prognostic marker in African American women with TNBC. CKYPB2 can further select patients with TNBC and ER positive tumors that will likely benefit from inhibitors of ribosomal RNA synthesis, CDK4 and nucleolin.
专利号:WO-2025137620-A1 优先权日:2023-12-21 标题:Methods for high quality and high accuracy methylation sequencing 发明人:KENNEDY ANDREW 权利人:GUARDANT HEALTH INC 摘要:Provided herein are methods and compositions for calibrating one or more base calling metrics in a sequencing by synthesis reaction, and for calling at least a portion of nucleobases in a converted region of a DNA molecule using the one or more calibrated base calling metrics. Provided herein are also methods for determining the likelihood that a subject has a disease or condition, such as cancer.
专利号:EP-4288444-A1 优先权日:2021-02-08 标题:Rationale, design, synthesis and validation of a small molecule anticancer agent
1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548818/ doi: 10.1177/1758835919833867. eCollection 2019. Review. 3: Poratti M, Marzaro G. Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib. Eur J Med Chem. 2019 Jun 15;172:143-153. doi: 10.1016/j.ejmech.2019.03.064. Epub 2019 Apr 4. Review. doi: 10.1007/s40259-019-00337-6. Review. doi: 10.1007/s10549-019-05133-y. Epub 2019 Jan 18. Review. doi: 10.18773/austprescr.2018.058. Epub 2018 Oct 2. Review. 7: Büyükkaramikli NC, de Groot S, Riemsma R, Fayter D, Armstrong N, Portegijs P, Duffy S, Kleijnen J, Al MJ. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2019 Feb;37(2):141-153. doi: 10.1007/s40273-018-0708-4. Review.
合成参考文献
参考文献:10.1007/s40262-020-00930-x 摘要:Groenland SL, Martínez-Chávez A, van Dongen MGJ, Beijnen JH, Schinkel AH, Huitema ADR, Steeghs N. Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib. Clin Pharmacokinet. 2020 Dec;59(12):1501–20. doi: 10.1007/s40262-020-00930-x.